Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pd-156707 SCHEMBL4178950 | 1.00 | EDNRA (1.00) | EDNRAEDNRB | |
| SCHEMBL8037823 | 0.94 | EDNRA (0.89) | EDNRAEDNRB | |
| SCHEMBL8031633 | 0.93 | EDNRA (0.86) | EDNRAEDNRB | |
| SCHEMBL8031720 | 0.93 | EDNRA (1.00) | EDNRAEDNRB | |
| SCHEMBL8035530 | 0.92 | EDNRA (0.85) | EDNRAEDNRB | |
| SCHEMBL8035497 | 0.92 | EDNRA (0.84) | EDNRAEDNRB | |
| SCHEMBL7956457 | 0.91 | EDNRA (1.00) | EDNRAEDNRB | |
| SCHEMBL8033478 | 0.91 | EDNRA (1.00) | EDNRAEDNRB | |
| SCHEMBL8021940 | 0.91 | EDNRA (0.84) | EDNRAEDNRB | |
| SCHEMBL8035371 | 0.91 | EDNRA (0.91) | EDNRAEDNRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3643309-B1 | NINTEDANIB FOR USE IN THE TREATMENT OF SYSTEMIC SCLERODERMA | BOEHRINGER INGELHEIM INT (DE) | 2025-12-03 | — | — | EP | disclosed |
| US-20230372297-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2023-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372297-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | MMP1, COL1A1, SMAD3 | EDNRA 41/4885EDNRB 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.